Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

143398

registered interest
date	07/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will issue a direction under Regulation 7 of the National Institue for Health and Care Excellence (NICE) (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 to exempt clinical commissioning groups from the requirement to comply with NICE Technology Assessment Guidance TA155, in order that NHS commissioners can make their own decision on whether to issue the drug Avastin and Lucentis.
tabling member constituency	West Bromwich East
tabling member printed	Mr Tom Watson
uin	213834
answer	answer is ministerial correction date of answer 17/11/2014 answer text <p>We have no such plans. The Government believes that drugs and treatments that are established as clinically and cost effective should be available to patients. The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance on Lucentis (ranibizumab) and Macugen (pegaptanib) for the treatment of age-related macular degeneration (TA155) that recommends Lucentis as a clinically and cost effective use of National Health Service resources for the treatment of patients with wet age-related macular degeneration meeting specific clinical criteria.</p><p> </p><p> </p><p> </p><p>Under Regulation 7, commissioners are legally required to make funding available so that clinicians can prescribe treatments recommended in NICE technology appraisal guidance to patients. This does not prevent commissioners from supporting the use of additional treatment options if they believe they would be of benefit to their local population.</p><p> </p><p> </p><p> </p><p>Avastin (bevacizumab) is not licensed for use in the treatment of wet age-related macular degeneration. Clinicians are able to prescribe drugs outside their marketing authorisation where they believe it is clinical appropriate, based on an assessment of their patient’s individual clinical circumstances.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 17/11/2014 11:14:36 answering member 4020 label Biography information for George Freeman
tabling member	1463 label Biography information for Lord Watson of Wyre Forest

143452

registered interest
date	07/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services: Foreign Nationals
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Earl Howe on 30 October (HL2329), what are the extra costs to the National Health Service of net immigration between 2001 and 2011.
tabling member printed	Lord Blencathra
uin	HL2737
answer	answer is ministerial correction date of answer 17/11/2014 answer text <p>The Department is not able to make a reliable estimate of the extra costs to the National Health Service budget of net immigration between 2001 and 2011, since the NHS does not hold or collate data on costs based on a person’s nationality or immigration status.</p><p> </p><p><strong> </strong></p><p> </p><p>In 2013, the Department commissioned a quantitative report to better understand the extent of the use of the NHS by migrants and visitors to support the consultation <em>Sustaining services, ensuring fairness: A consultation on migrant access and their financial contribution to NHS provision in England. </em>The report “Quantitative Assessment of Visitor and Migrant Use of the NHS in England. Exploring the Data.” estimates the total cost of visitors and temporary migrants’ normal use of NHS services to be £1.8 billion per year. This is the total gross cost and currently only a proportion of this is chargeable (approximately £460 million). Only some secondary care services are chargeable to non-European Economic Area individuals, and services for emergency care and public health reasons are exempt for all visitors and migrants, in addition to exemptions for different groups of individuals. This is an estimate for visitors and temporary migrants coming to England and does not account for the saving from individuals who migrate from the United Kingdom.</p><p> </p> answering member printed Earl Howe question first answered 17/11/2014 12:05:06 answering member 2000 label Biography information for Earl Howe
tabling member	497 label Biography information for Lord Blencathra

142203

registered interest
date	06/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Blood: Contamination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many applications to register with (a) the Skipton Fund Ltd and (b) MEFT Ltd have been refused on the grounds of incomplete hospital records since the inception of each such companies.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	213788
answer	answer is ministerial correction date of answer 11/11/2014 answer text <p>These data are not held centrally. The Skipton Fund has advised us that excluding people who clear the hepatitis C virus naturally within six months, a total of 508 claims have been rejected. The majority of these claims were rejected on the grounds of incomplete hospital records. This includes both claims made by living individuals and claims made in respect of people who have died. No claims for MFET Ltd have been rejected on the grounds of incomplete medical records.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/11/2014 16:04:12 answering member 3918 label Biography information for Jane Ellison
tabling member	1533 label Biography information for Dame Diana Johnson

142207

registered interest
date	06/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Genetic Engineering
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what his policy is on measures to alter the genes of babies; and if he will make a statement.
tabling member constituency	Christchurch
tabling member printed	Mr Christopher Chope
uin	213791
answer	answer is ministerial correction date of answer 11/11/2014 answer text <p>There are no plans or policy on measures to alter the genes of babies.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/11/2014 16:07:21 answering member 3918 label Biography information for Jane Ellison
tabling member	242 label Biography information for Sir Christopher Chope

142209

registered interest
date	06/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to paragraph 54 of the minutes of the meeting of 4 June 2014 of the Joint Committee on Vaccination and Immunisation, over what period of time Public Health England intends to revise the cost effectiveness model of pneumococcal polysaccharide vaccine to include the latest epidemiological data on pneumococcal disease in the UK; and if he will make a statement.
tabling member constituency	Chelmsford
tabling member printed	Mr Simon Burns
uin	213785
answer	answer is ministerial correction date of answer 11/11/2014 answer text <p>Public Health England (PHE) will review modelling undertaken on the impact and cost-effectiveness of the Pneumococcal Polysaccharide Vaccine (PPV) programme in over-65 year olds using the latest epidemiological data on invasive pneumococcal disease in the United Kingdom. PHE will report its findings to the Pneumococcal Sub-committee of the Joint Committee on Vaccination and Immunisation (JCVI). It is anticipated that the Pneumococcal Sub-committee will meet for the first time in spring 2015.</p><p> </p><p> </p><p> </p><p>At this meeting of the Pneumococcal Sub-committee members will review information including epidemiological data and PHE’s report on PPV impact and cost-effectiveness. Should all the required data be available to the Sub-committee, and subject to the requirement for additional meetings and, if required, additional modelling, it is anticipated that it will report to the JCVI main committee. The JCVI will form advice at the October 2015 meeting. The minutes of this meeting will be published in winter 2015.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/11/2014 15:48:49 answering member 3918 label Biography information for Jane Ellison
tabling member	46 label Biography information for Sir Simon Burns

142215

registered interest
date	06/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when a module on perinatal mental health will be included in all new midwives' training.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	213822
answer	answer is ministerial correction date of answer 11/11/2014 answer text <p>The Government has mandated Health Education England (HEE) to work with the Nursing and Midwifery Council and the Royal College of Midwives (RCM), to ensure that midwives in training have a core training module focussing on perinatal mental health with the intention that this will be in place for those entering midwifery training in 2015. In addition, by March 2015, HEE working with the RCM will develop a continuing professional education framework for the existing maternity and early years workforce so that all healthcare professionals who come into contact with women using maternity and post natal services have access to training to optimise the care and treatment of women with perinatal mental health illness.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 11/11/2014 11:43:54 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	4036 label Biography information for Luciana Berger

142218

registered interest
date	06/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: Mother and Baby Units
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the Government plans to start collecting data on the number of women admitted to perinatal inpatient mother and baby units.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	213823
answer	answer is ministerial correction date of answer 11/11/2014 answer text <p>Data on perinatal mental health admissions is provided by the Hospital Episode Statistics (HES). HES is a data warehouse containing details of all admissions, outpatient appointments and accident and emergency attendances at National Health Service hospitals in England, and is published by the Health &amp; Social Care Information Centre. HES does not identify specific units or types of unit, and as such will not be able to provide data on admissions to mother and baby units. The lowest level of data aggregation collected by HES is at provider site of treatment, i.e. the hospital.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 11/11/2014 11:44:46 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	4036 label Biography information for Luciana Berger

142229

registered interest
date	06/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pneumococcal Disease: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to paragraph 49 of the minutes of the meeting of 4 June 2014 of the Joint Committee on Vaccination and Immunisation (JCVI), when his Department indicated to the JCVI that it would like the JCVI to confirm or revise its conclusions regarding the pneumococcal conjugate vaccine of choice for the UK; how his Department indicated its wish to the JCVI; whether he is satisfied that the JCVI has complied with his Department's request; and if he will make a statement.
tabling member constituency	Chelmsford
tabling member printed	Mr Simon Burns
uin	213728
answer	answer is ministerial correction date of answer 11/11/2014 answer text <p>The request from the Department to the Joint Committee on Vaccination and Immunisation (JCVI) regarding the use of pneumococcal conjugate vaccine (PCV) in the United Kingdom was conveyed by Departmental officials via the JCVI secretariat within Public Health England in early 2014.</p><p> </p><p> </p><p> </p><p>At its meeting on 4 June 2014, the minutes of which are available on GOV.UK, the JCVI concluded that PCV13 should remain the pneumococcal conjugate vaccine of choice for the United Kingdom at this time. We have accepted this advice.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/11/2014 15:54:00 answering member 3918 label Biography information for Jane Ellison
tabling member	46 label Biography information for Sir Simon Burns

142602

registered interest
date	06/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Spinal Injuries
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what plans they have to support Professor Raisman’s research into spinal cord injury following the success of his first clinical trial in Poland.
tabling member printed	Baroness Tonge
uin	HL2706
answer	answer is ministerial correction date of answer 17/11/2014 answer text <p>Professor Raisman, currently at the University College London Institute of Neurology, has been developing this technique for around 40 years, 30 of which were spent at the Medical Research Council’s National Institute for Medical Research (NIMR). All of the basic research and animal proof of concept for this work was undertaken during Professor Raisman’s time at the NIMR and a summary of this work can be found at:</p><p> </p><p> </p><p> </p><p>www.nimr.mrc.ac.uk/news/clinical-success-for-research-programme-which-started-at-nimr/</p><p> </p><p> </p><p> </p><p>Since Professor Raisman left the NIMR the Medical Research Council (MRC) has been involved in guiding the clinical translation of this work, however the MRC is not currently supporting his research.</p><p> </p><p><strong> </strong></p><p> </p><p>The MRC always welcomes high quality applications for support into any aspect of human health. These are judged in open competition with other demands on funding and awards are made according to their scientific quality and importance to human health. When appropriate, high quality research in particular areas of strategic importance may be given priority in competition for funds, but research excellence and importance to health continue to be the primary considerations in funding decisions.</p><p> </p><p><strong> </strong></p><p> </p><p>The National Institute for Health Research (NIHR) funds eleven biomedical research centres that conduct translational research to transform scientific breakthroughs into benefits for patients. These centres are formed through partnerships between England’s leading National Health Service organisations and universities. The NIHR is investing £110 million over five years (2012-17) in the NIHR biomedical research centre at University College London Hospitals NHS Foundation Trust and University College London. The centre is supporting research on the use of cells from the lining of the nose to repair damaged nerves in the spinal cord.</p><p> </p> answering member printed Earl Howe question first answered 17/11/2014 12:46:04 answering member 2000 label Biography information for Earl Howe
tabling member	200 label Biography information for Baroness Tonge

114518

registered interest
date	05/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Hyperstimulation Syndrome
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answers by the Parliamentary Under-Secretary of State for Public Health, Jane Ellison, on 11 September (HC Deb, cols 664–5W) and on 12 September (HC Deb, col 750W), how the assessment was made that if "mitochondria donation was permitted in treatment it is not anticipated that this will impact on the incidence of ovarian hyperstimulation syndrome" in the absence of an evidence base to predict the cohort of patients that may develop ovarian hyperstimulation syndrome.
tabling member printed	Lord Alton of Liverpool
uin	HL2691
answer	answer is ministerial correction date of answer 17/11/2014 answer text <p>Further to answers given on 12 September (HC Deb, col 750w) the Human Fertilisation and Embryology Authority (HFEA) has advised that if mitochondrial donation was permitted in treatment it is not anticipated that this would impact on the incidence of ovarian hyper stimulation syndrome (OHSS). This is because any egg donation or collection processes necessary for mitochondrial donation would be carried out at HFEA licensed fertility clinics in line with the guidance outlined in the HFEA Code of Practice. Mitochondrial donation raises no new issues in respect of OHSS as the women who may donate eggs will be subject to the same protocols as those donating to fertility treatment.</p><p> </p> answering member printed Earl Howe question first answered 17/11/2014 12:06:01 answering member 2000 label Biography information for Earl Howe
tabling member	738 label Biography information for Lord Alton of Liverpool